Tidak mengudara

Berita berkelanjutan · 1 laporan

FDA panel review of seven unapproved peptides

Pertama tayang Terbaru tayang

Sedang berkembangPemeriksaan berikutnya : The committee’s recommendations on whether pharmacies may compound and dispense the seven peptides.

Perkembangan terkini

The FDA Pharmacy Compounding Advisory Committee began its two-day review of seven unapproved peptides on July 23. FDA career scientists recommended against compounding all seven, citing a lack of human clinical data for three and inadequate data for the others; the committee’s recommendations have not yet been reported.

Pelacak beritaHari ke-1

1 laporan11 media11 sumber1 video

  • Belum ada peristiwa bertanggal
    1. Pembaruan ke-1Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

    Perkembangan sejauh ini

    1. Pembaruan ke-1

      Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

      A two-day meeting in Washington ended with a narrow recommendation to loosen compounding rules for unapproved compounds championed by influencers and RFK Jr. — over the objections of the agency's own staff.

      Masih terbuka setelah laporan ini

      • Whether the FDA will adopt the committee's recommendation in full or in part.
      • Which specific peptides failed to win a majority, given the gap between seven on the agenda and six (or four) endorsed.

    Riwayat

    1. Dibuka1 laporan

    Siapa yang terlibat

    Tokoh

    • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 laporan
    • Robert F. Kennedy Jr.26th United States Secretary of Health and Human Services since 20251 laporan

    Tempat

    • ChinaChina1 laporan
    • WashingtonWashington, DC, USA1 laporan

    Semua media yang kami baca tentang berita ini

    11 sumber11 media1 video